Cisplatin pharmacokinetic
WebMar 1, 1998 · The pharmacokinetics[PK] of cisplatin are complicated. It is demonstrated that the analysis of PK for free platinum is appropriate to predict the pharmacodynamic [PD] … WebApr 21, 2004 · The pharmacokinetics of unbound and total cisplatin was each ascribed a two-compartment model with linear elimination. The parameters of the basic pharmacokinetic model were CL, the systemic …
Cisplatin pharmacokinetic
Did you know?
WebFeb 28, 2024 · One of the main problems in chemotherapy using platinum drugs as anticancer agents is the resistance phenomenon. Synthesizing and evaluating valid alternative compounds is challenging. This review focuses on the last two years of progress in the studies of platinum (II)- and platinum (IV)-based anticancer complexes. In … WebSep 21, 2016 · The pharmacokinetics and pharmacodynamics of docetaxel and cisplatin were compared in elderly and non-elderly patients. Results There were no differences in pharmacokinetics of docetaxel or cisplatin between elderly versus non-elderly patients with regard to clearance and volume of distribution.
WebDec 1, 2024 · Methods. In this open-label, randomized, phase III study, newly diagnosed patients with advanced NSCLC were initially randomized (R1, 1:1) to receive first-line treatment with cisplatin 75 mg/m 2 plus docetaxel 75 mg/m 2 (DC75) or 60 mg/m 2 (DC60) for up to 4 cycles. Patients without progression were further randomized (R2, 1:2) to best … WebJan 25, 2008 · For the cisplatin pharmacokinetic studies, the measured absorbance values for the 10 mice receiving cisplatin only were described with a one-compartment pharmacokinetic model. The measured absorbance values at 6 h for the two mice that received STS together with cisplatin were compared with the prediction for the model. …
WebJul 22, 2024 · Pharmacokinetics not affected by mild (Cl cr 50–80 mL/minute), moderate (Cl cr 30 to <50 mL/minute), or severe (Cl cr <30 mL/minute) renal impairment. Pharmacokinetics have not been evaluated in patients with renal impairment requiring dialysis. Common Adverse Effects WebJun 13, 2005 · Cisplatin, cisplatinum or cis-diamminedichloroplatinum (II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors.
WebDec 1, 1992 · The pharmacokinetic profile of vinorelbine is often described as a 3-compartment model characterised by a long terminal half-life that varies between 20 and 40 hours and a large apparent volume of distribution (Vd) of around 70 L/kg. 86 Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer D. Levêque, E. Quoix,
WebCisplatin is a platinum-based agent whose nephrotoxicity is thought related to the chloride in the cis position. Cisplatin gains entry into tubular cells via uptake by the OCT-2 … darren star movies and tv showsWebApr 5, 2024 · Pharmacokinetics. Distribution. Cisplatin dose not undergo the instantaneously and reversible binding to plasma protein that is characteristic of … bis pally tbcWebAug 1, 2005 · Alterations in the availability of binding proteins, fluid shifts, and acid-base changes can all influence chemotherapy pharmacokinetics. Furthermore, the pharmacodynamics of these drugs can be influenced by an increased exposure to a drug's active metabolites as well as to the agent itself. bis pally tank wotlkWebApr 10, 2024 · Triple-negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer and constitutes 10–20% of all breast cancer cases. Even though platinum-based drugs such as cisplatin and carboplatin are effective in TNBC patients, their toxicity and development of cancer drug resistance often hamper their clinical use. … darren stone shootingWebMar 2, 2005 · The pharmacokinetic model distinguished between active drug and their inactive (inert) metabolites in plasma and CSF. INTRODUCTION The platinum analogues, cisplatin and carboplatin, are chemically reactive anticancer drugs that produce a cytotoxic effect through platination of DNA and the formation of cross-links. bis pal prot wotlkbis pal retWebPharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. In vitro studies with plasma and urine demonstrated that, in contrast to cisplatin, CBDCA is a stable complex [t 1/2 - 37 degrees; plasma, 30 hr, and urine, 20 to 460 hr]. bispanthi